Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-T + CDX-1140 + Pembrolizumab in Incurable Epithelial Cancers
NCT05349890Phase 1Active, not recruiting
- Start
- Apr 2023
- Primary completion
- Apr 2027
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TCR-transduced T cells. Primary endpoints: Incidence of adverse events at 2 years and Severity of adverse events at 2 years. Started Apr 2023; status: active, not recruiting.
02
Drugs
TCR-transduced T cells
Beyond the preview
Go deeper on NCT05349890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349890.